So some very postive developments from the research program. But as usual, there seems to be a disconnect in what has previously been said and what is going on.

Per Imtesty’s transcript of the recent update, Don said this “We’re filing almost immediately within the next week or so for this program to commence. Patient enrollment should start as early as March. Maybe it will slip into April, but we will have patients enrolled in this very soon. We only need 100 patients and God knows there are way more than 100 patients available out there right now. We have set up with principal investigators already. This program will predominantly run in the United States. And the desired chemistry is not required to do this. The chemistry is in place, but we will still continue this chemistry program, because we believe that with positive results from this Phase II Trial, we should have data before mid-year, and quite possibly even sooner than that. The trial is only 28 days long and only has 100 patients”.

Todays  PR has no mention of this mini trial. If this trial had even started recruiting or was about to commence, it would appear to have been the perfect time to announce such. The only reference I see to a possible trial is this :

“These findings showcase the unique dual-mechanism of apabetalone as a potential therapeutic for COVID-19 and provide strong support for human trials”

“ It was a pleasure to work with Resverlogix and truly share information both ways, and contribute data for the basis of their clinical trials.”

Constant stringing along, will we every catch the carrot or will we die of exhuastion chasing it?